Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 15/20 | 0.58 |
| ▸ | DAO | P14920 | 1/20 | 0.57 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.52 |
| ▸ | CYTH3 | O43739 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | EPN1 | Q9Y6I3 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27999613 | 0.82 | NNMT (0.43) | HCAR2DAOHCAR3LMNAMAPK1 | |
| SCHEMBL15467909 | 0.79 | HCAR2 (0.56) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL16445300 | 0.79 | HCAR2 (0.60) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL5618892 | 0.77 | KMT2A (0.51) | MAPK1 | |
| SCHEMBL28261041 | 0.73 | MAPK1 (0.79) | HCAR2DAOHCAR3LMNAMAPK1 | |
| SCHEMBL5599509 | 0.73 | HCAR2 (1.00) | HCAR2DAOHCAR3 | |
| SCHEMBL220072 | 0.72 | — | — | |
| SCHEMBL28488240 | 0.72 | HCAR2 (0.43) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL28111052 | 0.72 | HCAR2 (0.45) | HCAR2DAOHCAR3CYTH3BTK | |
| SCHEMBL165390 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024133426-A1 | METHOD FOR CONTROLLING DIAMIDE RESISTANT PESTS AND COMPOUNDS THEREFOR | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-27 | — | — | WO | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-07 | — | — | US | disclosed |
| US-11124502-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200283422-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| US-10570120-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190276442-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-09-12 | — | — | US | disclosed |
| US-10189823-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-20160083372-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-24 | — | — | US | disclosed |
| US-9126956-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126956-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2014-02-13 | — | — | US | disclosed |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2014-02-13 | — | — | US | disclosed |
| WO-2014025891-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| US-7285569-B2 | Tricycles, their manufacture and use as pharmaceutical agents | HOFF HOFFMANN-LA ROCHE INC. (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1793822-A1 | TRICYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. Hoffmann-Roche AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| US-20060069145-A1 | Tricycles, their manufacture and use as pharmaceutical agents | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | disclosed |
| WO-2006032519-A1 | TRICYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283422-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 658/4885DAO 1503/4885HCAR3 347/4885 |
| US-20140045906-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 658/4885DAO 1503/4885HCAR3 347/4885 |
| US-20160083372-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 658/4885DAO 1503/4885HCAR3 347/4885 |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 658/4885DAO 1503/4885HCAR3 347/4885 |
| US-11634413-B2 | Neprilysin inhibitors | MME, REN, ACE | HCAR2 658/4885DAO 1503/4885HCAR3 347/4885 |
| US-11124502-B2 | Neprilysin inhibitors | MME, REN, ACE | HCAR2 658/4885DAO 1503/4885HCAR3 347/4885 |
| US-20230312537-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 658/4885DAO 1503/4885HCAR3 347/4885 |
| US-20060069145-A1 | Tricycles, their manufacture and use as pharmaceutical agents | ABCB1, CYP3A43, CYP3A5 | HCAR2 2141/4885DAO 4172/4885HCAR3 3136/4885 |
| US-10189823-B2 | Neprilysin inhibitors | MME, REN, ACE | HCAR2 658/4885DAO 1503/4885HCAR3 347/4885 |
| US-20190276442-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | HCAR2 658/4885DAO 1503/4885HCAR3 347/4885 |
| US-10570120-B2 | Neprilysin inhibitors | MME, REN, ACE | HCAR2 658/4885DAO 1503/4885HCAR3 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.